SCHEMBL1099587

SCHEMBL1099587

CCS(=O)(=O)Nc1sc2ccccc2c1C(C)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACLY P53396 1/20 0.47
▸ ABCC1 P33527 1/20 0.45
▸ ABCG2 Q9UNQ0 1/20 0.45
▸ LMNA P02545 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ MAPT P10636 2/20 0.41
▸ HPGD P15428 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ HSD17B10 Q99714 1/20 0.40
▸ CNR2 P34972 4/20 0.39
▸ CNR1 P21554 2/20 0.39
▸ ACACB O00763 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ ACACA Q13085 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15199357 0.82 ACLY (0.62) ACLYABCC1ABCG2LMNAMAPK1
SCHEMBL1099843 0.78 ACLY (0.54) ACLYLMNAMAPTMEN1KMT2A
SCHEMBL10299809 0.77 PSIP1 (0.41) ACLYABCC1ABCG2LMNAMAPT
SCHEMBL1098725 0.75 ACLY (0.51) ACLYLMNAMAPK1MAPTHPGD
SCHEMBL1100199 0.75 ACLY (0.51) ACLYKDM4EHSD11B1
SCHEMBL10280855 0.70 HSD11B1 (0.50) ACLYABCC1ABCG2LMNAMAPK1
SCHEMBL12469951 0.70 CNR2 (0.63) ACLYLMNAMAPTHPGDKDM4E
SCHEMBL11379316 0.70 LMNA (0.49) LMNAMAPK1MAPTGAAMEN1
SCHEMBL9556945 0.70 LMNA (0.49) LMNAMAPK1MAPTHPGDKDM4E
SCHEMBL12469781 0.70 ACLY (0.76) ACLYABCC1ABCG2LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 — — US disclosed
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 — — US disclosed
US-9434711-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2016-09-06 — — US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 — — US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 — — US disclosed
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 — — US disclosed
CN-101801949-B Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2014-09-24 — — CN disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 — — US disclosed
US-8809327-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-08-19 — — US disclosed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 — — EP disclosed
US-8216547-B2 Radiolabelled TRP M8 receptor ligands JANSSEN PHARMACEUTICA NV (BE) 2012-07-10 — — US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 — — US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 — — US disclosed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 — — US disclosed
CN-101801949-A Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2010-08-11 — — CN disclosed
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS JANSSEN PHARMACEUTICA NV (BE) 2010-01-21 — — US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 — — US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 — — US disclosed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 — — US disclosed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100015053-A1 RADIOLABELLED TRP M8 RECEPTOR LIGANDS TRPM8, TRPM7, GPR68 ACLY 4684/4885ABCC1 1416/4885ABCG2 673/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ACLY 1333/4885ABCC1 485/4885ABCG2 517/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 ACLY 1333/4885ABCC1 485/4885ABCG2 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback